Tier 2 — strong

Combined metabolic activators therapy ameliorates liver fat in nonalcoholic fatty liver disease patients

Zeybel M, Altay O, Arif M, Li X, Yang H, Fredolini C, Akyildiz M, Saglam B, Gonenli MG, Ural D, Kim W, Schwenk JM, Zhang C, Shoaie S, Nielsen J, Uhlén M, Borén J, Mardinoglu A
Molecular systems biology 2021 17; 10; e10459

Bibliography

PubMed
PMID 34694070
PubMed Central
PMC8724764
DOI
10.15252/msb.202110459
Funding
Funding details are not specified in the accessible publication information.
Competing interests
Disclosures include founder/shareholder relationships with ScandiBio Therapeutics and ScandiEdge Therapeutics.

Study snapshot

DesignRandomized controlled study of a multi-ingredient or combined intervention
ModelHuman participants
Sample32 adults with NAFLD randomized
InterventionNR with serine, NAC and carnitine tartrate versus placebo
Duration10 weeks
EndpointsLiver fat; liver enzymes; multi-omics measures

What the study showed, in plain terms

The multi-ingredient treatment reduced liver-fat and selected laboratory measures in this small NAFLD trial.

Key findings

The multi-ingredient treatment reduced liver-fat and selected laboratory measures in this small NAFLD trial.

What this study can and cannot tell us

A combination intervention with a small sample; no NR-only effect, long-term liver outcome or fibrosis reversal is established.

Related papers in the corpus

Tier 2
Multi-omics characterization of improved cognitive functions in Parkinson's disease patients after the combined metabolic activator treatment: a randomized, double-blinded, placebo-controlled phase II trial
Yulug B et al. · Brain communications · 2025
Tier 2
Combined metabolic activators improve cognitive functions in Alzheimer's disease patients: a randomised, double-blinded, placebo-controlled phase-II trial
Yulug B et al. · Translational neurodegeneration · 2023
Tier 2
The acute effect of different NAD + precursors included in the combined metabolic activators
Li X et al. · Free radical biology & medicine · 2023
Tier 2
Combined Metabolic Activators Accelerates Recovery in Mild-to-Moderate COVID-19
Altay O et al. · Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2021

Citation network

Articles citing this research paper

1 article

Biohack Blueprint analyses that reference this study in their evidence base.

Editorial review

Reviewed by the Biohack Blueprint research team

Last verified

Dr. Khaled Mahmoud, MBBChCritical Care Medicine, Longevity Science & Editorial Direction Dr. Amr Yasser, PhDCardiometabolic, Musculoskeletal, Gut & Bioavailability Dr. Abdulla Mostafa, PhDCellular Senescence, Neurological, Mitochondrial & Brain-Ageing Biology